Bela P. Merkely
Distinguished in Heart Failure

Bela P. Merkely

78/A Üllői Street, 
Budapest, BU, HU 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Heart Failure
78/A Üllői Street, 
Budapest, BU, HU 
OverviewLocationsClinical Research

Overview

Bela Merkely practices in Budapest, Hungary. Mr. Merkely is rated as a Distinguished expert by MediFind in the treatment of Heart Failure. His top areas of expertise are Heart Failure, Ventricular Fibrillation, Heart Attack, Heart Transplant, and Percutaneous Coronary Intervention (PCI).

His clinical research consists of co-authoring 949 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 216 articles and participated in 1 clinical trial in the study of Heart Failure.

Gender
Male

Locations

78/A Üllői Street, Budapest, BU 1083, Hungary
Other Locations
78 Üllői St, Budapest, BU 1082, Hungary
68 Városmajor Street, Varosmajor, BU, Hungary
41 Mária Street, Budapest, BU 1085, Hungary

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

CRT-DRIVE: Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment
CRT-DRIVE: Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment
Enrollment Status: Recruiting
Publish Date: October 24, 2024
Intervention Type: Device
Study Phase: Not Applicable
Secondary Prevention of Cardiovascular Disease in the Elderly Trial
Secondary Prevention of Cardiovascular Disease in the Elderly Trial
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: Cardiovascular Polypill, Treatment Prevention for Secondary CV
Study Phase: Phase 3
A Prospective, Randomized, Multi-center Study to Assess the Safety of the Orsiro Mission Stent Compared to the Resolute Onyx Stent in Subjects at High Risk for Bleeding in Combination With 1-month Dual Antiplatelet Therapy (DAPT)
A Prospective, Randomized, Multi-center Study to Assess the Safety of the Orsiro Mission Stent Compared to the Resolute Onyx Stent in Subjects at High Risk for Bleeding in Combination With 1-month Dual Antiplatelet Therapy (DAPT)
Enrollment Status: Completed
Publish Date: June 07, 2024
Intervention Type: Device
Study Phase: Phase 4
Clinical Evaluation of Safety and Effectiveness of the BackBeat Medical Moderato System in Patients With Hypertension: A Double-Blind Randomized Trial
Clinical Evaluation of Safety and Effectiveness of the BackBeat Medical Moderato System in Patients With Hypertension: A Double-Blind Randomized Trial
Enrollment Status: Unknown
Publish Date: December 14, 2022
Intervention Type: Device
Study Phase: Not Applicable
Open-Label, Randomised, Active Controlled, Multi-Centre Ph 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Acute HIT
Open-Label, Randomised, Active Controlled, Multi-Centre Ph 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Acute HIT
Enrollment Status: Terminated
Publish Date: December 08, 2022
Intervention Type: Drug
Study Phase: Phase 3
Addendum to Protocol CS-03: Clinical Evaluation of Safety and Effectiveness of the BackBeat Medical Moderato System in Patients With Hypertension: A Double-Blind Randomized Trial, NCT02837445
Addendum to Protocol CS-03: Clinical Evaluation of Safety and Effectiveness of the BackBeat Medical Moderato System in Patients With Hypertension: A Double-Blind Randomized Trial, NCT02837445
Enrollment Status: Unknown
Publish Date: November 03, 2022
Intervention Type: Device
Study Phase: Phase 1/Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination With Filgrastim in Early Recovery Post-Myocardial Infarction
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination With Filgrastim in Early Recovery Post-Myocardial Infarction
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Drug
Study Phase: Phase 2
Follow-up Registry of Heart Transplant Recipients, to Determine Long Term Outcome and Need for Further Interventional and Non-interventional Procedures
Follow-up Registry of Heart Transplant Recipients, to Determine Long Term Outcome and Need for Further Interventional and Non-interventional Procedures
Enrollment Status: Completed
Publish Date: April 23, 2021
A Single-Center Case Series Clinical Study to Assess the Feasibility of Integrating Therapeutic Hypothermia Using the ZOLL IVTM System as an Adjunctive Therapy to Percutaneous Coronary Intervention in Patients With AMI
A Single-Center Case Series Clinical Study to Assess the Feasibility of Integrating Therapeutic Hypothermia Using the ZOLL IVTM System as an Adjunctive Therapy to Percutaneous Coronary Intervention in Patients With AMI
Enrollment Status: Completed
Publish Date: November 27, 2020
Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe
Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe
Enrollment Status: Completed
Publish Date: March 24, 2020
Prospective, Single Arm, Multi-centre, Observational Registry to Further Validate Safety and Efficacy of the Ultimaster Des System in Unselected Patients Representing Everyday Clinical Practice
Prospective, Single Arm, Multi-centre, Observational Registry to Further Validate Safety and Efficacy of the Ultimaster Des System in Unselected Patients Representing Everyday Clinical Practice
Enrollment Status: Unknown
Publish Date: October 08, 2019
A Randomized, Double-blind, Multi-centre Study to Assess Safety and Efficacy of Incremental Doses of QGC001 in Patients With NYHA Class II/III Chronic Heart Failure (HF) With Left Ventricular Systolic Dysfunction Versus Placebo.
A Randomized, Double-blind, Multi-centre Study to Assess Safety and Efficacy of Incremental Doses of QGC001 in Patients With NYHA Class II/III Chronic Heart Failure (HF) With Left Ventricular Systolic Dysfunction Versus Placebo.
Enrollment Status: Terminated
Publish Date: October 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

949 Total Publications

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.
Journal: The New England journal of medicine
Published: September 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Merkely's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 34 Advanced Conditions
    View All 60 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile